Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06498128

Registry to Collect Information on Pregnancy, Neonatal, and Infant Outcomes in Pregnant Women Exposed to QUVIVIQ®

This study will investigate pregnancy, neonatal, and infant outcomes in women exposed to QUVIVIQ during pregnancy compared to women unexposed to QUVIVIQ during pregnancy.

Recruiting

Interested in participating?

Request Info

Key information

Age range

15 year–50 year

Sex eligibility

Female

Study type

Observational

Primary location

Jodha Tishon, Toronto, Ontario, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

A) Eligibility criteria for prospective pregnancies:

Inclusion criteria

  • Diagnosis of insomnia disorder prior to pregnancy.
  • Pregnancy is ongoing and outcome of pregnancy (i.e., pregnancy loss or live birth) is not known.
  • One of the following:
  • Exposure to QUVIVIQ at any time during the current pregnancy or within 5 half-lives prior to conception.
  • Exposure to other, non-orexin receptor antagonist medications for insomnia during pregnancy or within 5 half-lives of the respective insomnia medication prior to conception.
  • No exposure to any insomnia medication during pregnancy and within 5 half-lives of any insomnia medication taken prior to conception.

Exclusion criteria

  • Exposure to any orexin receptor antagonist other than QUVIVIQ - including BELSOMRA® (suvorexant), DAYVIGO® (lemborexant), any orexin receptor antagonist newly approved during the study period, or any orexin receptor antagonist in pre-market clinical studies - during the current pregnancy or within 5 half-lives of the respective medication prior to conception.

B) Eligibility criteria for retrospective pregnancies:

Inclusion criteria

  • Diagnosis of insomnia disorder prior to pregnancy.
  • Pregnancy has ended.
  • Exposure to QUVIVIQ during pregnancy or within 5 half-lives prior to conception.

Exclusion criteria

  • Exposure to any orexin receptor antagonist other than QUVIVIQ - including suvorexant, lemborexant, any orexin receptor antagonist newly approved during the study period, or any orexin receptor antagonist in pre-market clinical studies - during pregnancy or within 5 half-lives of the respective medication prior to conception.

Treatment and study plan

Daridorexant

Drug

Dosing and treatment duration of QUVIVIQ as part of this observational study is at the discretion of the healthcare provider in accordance with local clinical practice and local labeling.

Other names: QUVIVIQ

Non-orexin receptor antagonist medications for insomnia

Drug

Dosing and treatment duration of non-orexin receptor antagonist medications for insomnia as part of this observational study is at the discretion of the healthcare provider in accordance with local clinical practice and local labeling.

No insomnia medication

Other

No insomnia medication was administered.

Primary outcomes

  1. Major congenital malformations classified according to MACDP

    Time frame: Start of pregnancy up to 1 year of infant age

    Congenital malformations will be classified according to the Metropolitan Atlanta Congenital Defects Program (MACDP) classification system. All potential major congenital malformations identified by the participant's or the infant's healthcare providers will be evaluated by a qualified, independent committee of at least 3 teratologists using all available medical records. Classification will be based upon the teratologists' adjudication, who will be blinded to participant exposure status.

Secondary outcomes

  1. Pregnancy complications - number of participants with pre-eclampsia

    Time frame: 20 weeks gestation until delivery/birth/labor

    The presence of hypertension on 2 occasions at least 4 hours apart after 20 weeks gestation (in a woman with previously normal blood pressure) and proteinuria; or, in the absence of proteinuria, a new onset of hypertension accompanied by one of the following conditions: thrombocytopenia, renal insufficiency, impaired liver function, pulmonary edema, or cerebral or visual symptoms.

  2. Pregnancy complications - number of participants with pregnancy-induced hypertension

    Time frame: 20 weeks gestation until delivery/birth/labor

    High blood pressure associated with pregnancy, as diagnosed by the treating healthcare provider, i.e., elevated (systolic between 120-129 mmHg and diastolic less than 80 mmHg); Stage 1 hypertension (systolic between 130-139 mmHg or diastolic between 80-89 mmHg); or Stage 2 hypertension (systolic at least 140 mmHg or diastolic at least 90 mmHg).

  3. Pregnancy complications - number of participants with pre-term labor

    Time frame: Start of pregnancy up to 37 weeks gestation

    Regular contractions of the uterus resulting in changes in the cervix that start before 37 weeks of pregnancy.

  4. Pregnancy complications - number of participants with gestational diabetes

    Time frame: Start of pregnancy until delivery/birth/labor

    Characterized by the development of carbohydrate intolerance with first onset or first recognition during pregnancy.

  5. Pregnancy outcomes - number of participants with pregnancy outcome of elective or therapeutic pregnancy termination

    Time frame: Start of pregnancy until delivery/birth/labor

    Any induced or voluntary fetal loss during pregnancy.

  6. Pregnancy outcomes - number of participants with pregnancy outcome of spontaneous abortion

    Time frame: Start of pregnancy up to 20 weeks gestation

    Loss of a fetus due to natural causes at less than 20 weeks of gestation.

  7. Pregnancy outcomes - number of participants with pregnancy outcome of fetal death or stillbirth

    Time frame: 20 weeks gestation up to birth

    Death of a fetus at or after 20 weeks of gestation.

  8. Pregnancy outcomes - number of participants with pregnancy outcome of live birth

    Time frame: 37 weeks gestation up to 40 weeks gestation

    Birth of a surviving neonate.

  9. Pregnancy outcomes - number of participants with pregnancy outcome of pre-term birth

    Time frame: Less than 34 weeks gestation up to 37 weeks gestation

    Live birth prior to 37 weeks gestation: early preterm (< 34 weeks), late preterm (34-36 weeks), and early term (37-38 weeks).

  10. Infant outcomes - number of infants with outcome of minor congenital malformations classified according to MACDP

    Time frame: Start of pregnancy up to 1 year of infant age

    Congenital malformations will be classified according to the Metropolitan Atlanta Congenital Defects Program (MACDP) classification system. All potential minor congenital malformations will be evaluated by at least 3, qualified, independent teratologists using all available medical records. Classification will be based upon the teratologists' adjudication, who will be blinded to participant exposure status.

  11. Infant outcomes - infants categorized according to size for gestational age

    Time frame: At birth of infant

    All live births will be classified using the World Health Organization definition of birth weight, i.e., small (below the 10th percentile), appropriate (between the 10th and 90th percentile), or large (above the 90th percentile) for gestational age.

  12. Infant outcomes - number of infants with outcome of low birth weight

    Time frame: At birth of infant

    Birth weight of less than 2500 g; subclassified into very low birth weight (< 1500 g) and moderately low birth weight (1500 g to 2499 g).

  13. Infant outcomes - number of infants with outcome of infant death

    Time frame: Birth of infant up to 1 year of infant age

    Death of a live-born infant within the first year of life; subclassified as neonatal deaths (≤ 28 days of life) and infant deaths (29 to 365 days of life).

  14. Infant outcomes - number of infants with outcome of hospitalization for serious illness

    Time frame: Birth of infant up to 1 year of infant age

    In-patient admissions for treatment of potentially life threatening illnesses among live-born infants within the first year of life.

  15. Infant outcomes - postnatal growth and development - weight-for-length

    Time frame: Birth of infant up to 1 year of infant age

    World Health Organization Growth Charts (suitable for use in the US and EEA from birth to 24 months) will be applied for this study, where infant growth measurements will be used to estimate gender-specific weight-for-length percentiles (weight in kilograms, length in centimeters).

  16. Infant outcomes - postnatal growth and development - head circumference-for-age

    Time frame: Birth of infant up to 1 year of infant age

    World Health Organization Growth Charts (suitable for use in the US and EEA from birth to 24 months) will be applied for this study, where infant growth measurements will be used to estimate gender-specific head circumference-for-age percentiles (head circumference in centimeters, age in months and years).

  17. Infant outcomes - postnatal growth and development - length-for-age

    Time frame: Birth of infant up to 1 year of infant age

    World Health Organization Growth Charts (suitable for use in the US and EEA from birth to 24 months) will be applied for this study, where infant growth measurements will be used to estimate gender-specific length-for-age percentiles (length in centimeters, age in months and years).

  18. Infant outcomes - postnatal growth and development - weight-for-age

    Time frame: Birth of infant up to 1 year of infant age

    World Health Organization Growth Charts (suitable for use in the US and EEA from birth to 24 months) will be applied for this study, where infant growth measurements will be used to estimate gender-specific weight-for-age percentiles (weight in kilograms, age in months and years).

Study contacts

Contact information is provided by the study sponsor or research team.

Clinical Trial Information Europe

CONTACT

[email protected]

+41 58 844 19 77

Clinical Trial Information USA

CONTACT

[email protected]

+1 856 661 37 21

Sponsors and collaborators

Lead sponsor

Idorsia Pharmaceuticals Ltd.

Industry

Collaborators

  • IQVIA Pty Ltd

Registry information

Official study title

QUVIVIQ® Pregnancy Registry

Important dates

Study start
2024
Primary completion
2033
Study completion
2033
First posted
Jul 12, 2024
Registry last updated
Dec 2, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.